What it's for (Indications)
- Insulin detemir is indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus.
- Specifically, it is approved for use in adult and pediatric patients aged 1 year and older with Type 1 Diabetes Mellitus, and in adult patients with Type 2 Diabetes Mellitus.
- As a long-acting basal insulin analog, it is designed to provide a relatively constant, peakless level of insulin over an extended period, mimicking the body's natural basal insulin secretion.
- It is typically used once or twice daily and is often administered in conjunction with mealtime (bolus) insulin for Type 1 diabetes, or with oral antidiabetic agents and/or mealtime insulin for Type 2 diabetes, to achieve optimal glycemic targets as determined by healthcare professionals.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The dosage of insulin detemir must be individualized based on the patient's metabolic needs, blood glucose monitoring results, and glycemic goals. It is administered by subcutaneous injection into the thigh, abdominal wall, or deltoid. Rotation of injection sites within the same region is recommended to reduce the risk of lipodystrophy. Insulin detemir should not be administered intravenously, as it can lead to severe hypoglycemia. For Type 1 diabetes, the typical starting dose is approximately one-third to one-half of the total daily insulin requirement. For Type 2 diabetes, a common starting dose is 0.1-0.2 units/kg once daily or 10 units once daily, adjusted based on individual glycemic response. If administered once daily, it should be given in the evening with the evening meal or at bedtime. If administered twice daily, the evening dose can be given with the evening meal, at bedtime, or approximately 12 hours after the morning dose. Dose adjustments should be made carefully and under medical supervision, with frequent monitoring of blood glucose levels. |
Safety & Warnings
Common Side Effects
- The most common and serious side effect associated with insulin detemir, like all insulin preparations, is hypoglycemia, which can range from mild to severe and potentially life-threatening.
- Other common side effects include injection site reactions such as pain, redness, itching, swelling, or bruising, which are generally mild and transient.
- Lipodystrophy (lipoatrophy or lipohypertrophy) can occur at the injection sites, especially if sites are not rotated.
- Weight gain is also a frequently observed side effect.
- Less common but serious adverse events include hypersensitivity reactions, which can manifest as generalized rash, itching, sweating, gastrointestinal upset, angioedema, difficulty breathing, palpitations, and fainting.
- Anaphylaxis is rare but can occur.
- Peripheral edema, temporary visual disturbances (due to transient changes in blood glucose control), and hypokalemia (due to intracellular shift of potassium) are also possible, especially with rapid and significant improvements in glycemic control.
Serious Warnings
- Black Box Warning: While insulin detemir does not carry an FDA-mandated Black Box Warning, several serious warnings and precautions warrant significant attention from healthcare providers and patients to ensure safe and effective use. These 'Serious Warnings' highlight critical safety information: **Serious Warnings** **Risk of Hypoglycemia:** All insulin products, including insulin detemir, can cause severe hypoglycemia, which may be life-threatening. This is the most common adverse effect. Patients must be educated on the signs, symptoms, and appropriate management of hypoglycemia. The risk is increased with intensive insulin therapy, changes in meal patterns, increased physical activity, renal or hepatic impairment, and concurrent use of certain medications. **Hypersensitivity Reactions:** Severe, life-threatening generalized allergic reactions, including anaphylaxis, can occur with insulin products. Patients should be advised to seek immediate medical attention if they experience symptoms such as a generalized rash, itching, sweating, angioedema, bronchospasm, or hypotension. **Fluid Retention and Heart Failure with Thiazolidinediones (TZDs):** Co-administration of insulin, including insulin detemir, with TZDs can cause dose-related fluid retention, which may lead to or exacerbate heart failure. This risk is particularly elevated in patients with pre-existing heart failure. Healthcare providers should monitor patients for signs and symptoms of heart failure and consider TZD discontinuation or dose reduction if these develop. **Never Share Insulin Pens:** Insulin pens are for single-patient use only. Sharing insulin pens between patients carries a significant risk of transmission of blood-borne pathogens, even if the needle is changed. Patients must be strictly advised not to share their insulin pens. **Medication Errors:** Accidental mix-ups between insulin products or with other injectable medications can occur due to similar packaging or names. Patients should always visually inspect the insulin product name and concentration on the label before each injection to prevent medication errors, which can result in either underdosing or overdosing of insulin.
- Several critical warnings are associated with insulin detemir use.
- The most prominent risk is **hypoglycemia**, which can be severe, leading to loss of consciousness, seizures, brain damage, and death.
- Patients and caregivers must be thoroughly educated on the symptoms, prevention, and treatment of hypoglycemia.
- **Hypersensitivity reactions**, including generalized skin reactions and severe, potentially life-threatening anaphylaxis, may occur; immediate medical attention is required for such events.
- **Hypokalemia** can occur due to insulin's effect on shifting potassium intracellularly, particularly in patients at risk or on concomitant potassium-lowering medications; close monitoring is advised.
- **Fluid retention and heart failure** have been observed when insulin, including insulin detemir, is co-administered with thiazolidinediones (TZDs), especially in patients with pre-existing heart failure; careful monitoring for signs and symptoms of heart failure is crucial.
- **Never share insulin pens** between patients, even if the needle is changed, due to the high risk of transmitting blood-borne pathogens.
- Patients should also be advised to **rotate injection sites** to minimize lipodystrophy and check the insulin product name and concentration before each injection to prevent **medication errors**.
How it Works (Mechanism of Action)
Insulin detemir is a long-acting human insulin analog developed through recombinant DNA technology. Its glucose-lowering action is primarily achieved by binding to insulin receptors on target cells, thereby promoting the cellular uptake of glucose in muscle and adipose tissue, and simultaneously inhibiting hepatic glucose production (gluconeogenesis and glycogenolysis). The prolonged action and relatively peakless profile of insulin detemir are attributed to a unique mechanism involving its fatty acid side chain, which allows for reversible binding to albumin in the bloodstream, creating a circulating depot. Additionally, after subcutaneous injection, insulin detemir forms soluble hexamers that slowly dissociate, further delaying its absorption into the systemic circulation. These two mechanisms combine to provide a stable, basal insulin level that typically lasts for up to 24 hours, thereby contributing to sustained glycemic control throughout the day and night.
Commercial Brands (Alternatives)
No other brands found for this formula.